Growth in US drug market slows in 2022, finds new report

Research from IQVIA shows that the use of medicines in the USA is slowing, with growth down to 5% in 2022, reaching a total value of $429 billion on a net price basis.

At the same time, out-of-pocket costs for patients in the country remain low, below $10 on average, as branded drugs have been generally less subject to price increases.

In its newly-released  report, IQVIA identified several factors to explain the evolving market, with an increase in health service use and the entry of new medicines into the market driving growth on the one hand.